IBDoc® is now available in Australia. IBDoc® achieved the CE certification in April 2015 for self-testing making it available to patients throughout Europe. Now a second major milestone has been reached. The Australian Health Authorities TGA (Therapeutic Goods Administration), approved the use of IBDoc®. This means that IBDoc® can now be made available to all Australian IBD patients
IBDoc News
In a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. They found 233 separate apps on Google Play Store (Android) and Apple App Store (iPhone) that matched their search criteria for IBD. Out of this inital apps they included
In addition to Czech, Hungarian, Estonian and Croatian, IBDoc is now also available in Polish. You can find the instruction for use in Polish here.
Today we added 4 more language translations to IBDoc® and it is now available in: Danish Czech Croatian Hungarian IBDoc® is not supported in 17 languages
The Canadian Digestive Health Foundation (CDHF) has recently produced a very interesting video about the use of calprotectin to confirm and predict flares in inflammatory bowel disease patients and how it can be used to manage IBD.
This year the United European Gastroenterology Week took place from October 24th to 28th in Barcelona. Over 13 000 participants from 114 countries were present. The BÜHLMANN team was among the 2325 exhibitors. This year’s UEGW marked an important event for us with the publication of the first clinical usability evaluation of IBDoc®. The data
Patient M.K. was one of the first patient to use IBDoc world wide during an early project in Vienna. M.K. is suffering from Crohn’s Disease and after the first couple of months of using IBDoc we received following statement:
A blog article about IBDoc® has been published on the Gastroenterology & Endoscopy News website, a No. 1-rated independent monthly newspaper providing news and information for nearly 18,000 gastroenterologists, colorectal surgeons, hepatologists, physician assistants and nurse practitioners. In the article Toronto-based medical journalist David Wild looked at the IBDoc® system and interviewed Dr. Peter Higgins, MD, the director
Basel, April 2nd, 2015 – BÜHLMANN is pleased to announce the launch of IBDoc®, the first in-vitro diagnostic test to measure the fecal inflammation marker calprotectin at home. IBDoc® just received a CE mark for patient self testing and is a revolutionary new test for gut inflammation aimed at people with Inflammatory Bowel Disease, Crohn’s and Ulcerative Colitis
Thank you for finding your way to this first blogpost from ibdoc.net. What is ibdoc.net? To understand that, you need to know first a few things about IBD, calprotectin and BÜHLMANN Laboratories AG, situated in Schönenbuch close to Basel, Switzerland. BÜHLMANN is well known for its faecal calprotectin tests, which are used by many medical